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Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease and is
highly prevalent in populations with metabolic conditions such as obesity and type II diabetes. Specific types of
Sasang constitution can act as a risk factor for metabolic diseases, but there are no studies addressing the
association between the Sasang constitutional types (SCTs) and NAFLD.
Methods: A total of 1184 individuals (508 males, 676 females) that enrolled in the Korean Genome and Epidemiology
Study were included in the present study. Classification of SCTs was done with an integrated diagnostic model. NAFLD
was diagnosed when the liver attenuation index (LAI) value was <5 Hounsfield units using computed tomography.
Relationships between the SCTs and NAFLD were analyzed using multiple logistic regressions.
Results: The average LAI was 13.3 ± 6.0 in the So-eum (SE) type, 12.3 ± 7.0 in the So-yang (SY) type, and 6.5 ± 9.9 in
the Tae-eum (TE) type. Prevalence of NAFLD was 4.7 % in the SE type, 14.0 % in the SY type, and 34 % in the TE type.
Even after adjusting for possible confounders, the SY and TE types continued to show a 3.90-fold (95 % CI, 1.60-9.51;
P = 0.0028) and 3.36-fold (95 % CI, 1.42-7.92; P = 0.0057) increase in chance of having NAFLD, respectively, compared
with the SE type. In the additional analysis including only non-obese subjects, the odds ratio of NAFLD was 3.27
(95 % CI, 1.29-8.29; P = 0.0126) in the SY type and 3.53 (95 % CI, 1.30-9.58; P = 0.0134) in the TE type compared with SE
type. In the multivariate analysis to determine which parameter had an independent association with NAFLD, higher
body mass index, alanine aminotransferase (ALT), triglyceride (TG), and low high-density lipoprotein cholesterol were
independently associated with developing NAFLD in the SY type. In contrast, male sex, alcohol consumption, higher
ALT, TG, and fasting glucose were risk factors for NAFLD in the TE type.
Conclusions: These results indicated that the SY and TE types are independent risk factors for NAFLD.
Keywords: Non-alcoholic fatty liver disease, Sasang constitutional types, Liver attenuation index, Computed tomography
Background
Sasang constitutional medicine (SCM), one of Korea’s trad-
itional medicines, was initiated by Jema Lee (1837–1900)
and has a history of more than 100 years of practice [1].
In SCM, people can be classified into four types, the
Sasang constitutional types (SCTs), based on the theory
that each SCT has specific physiological, physical, and
psychological traits, different responses to herbs and
sensitivities to pathologic conditions, and different in-
ternal organ functional activity [2, 3]. The four groups are:
Tae-yang (TY), Tae-eum (TE), So-yang (SY), and So-eum
(SE). According to the traditional SCM theory, each SCT
represents different temperaments, body shapes, and func-
tional activity of the four viscera - lungs, liver, spleen, and
kidneys [2, 3]. It has been suggested that the TY type is
progressive, positive, and has a more developed lung and
nape of the neck area and a less developed liver area. The
TE type has a gentle, commercial, and endurable per-
sonality, and has a more developed liver area and a less
developed lung area. Typically, the SE type can be
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characterized by a negative, selfish, and nervous
personality, and people who are belonged to this type
typically have a more developed kidney and a less
developed spleen. The SY type has temperament of
unstable and easily gets bored. Unlike the SE type,
people who are classified as the SY type had a more
developed spleen area and a less developed spleen area.
Several studies have also shown that specific SCTs are
prone to specific chronic diseases (e.g., hypertension
(HTN), diabetes mellitus (DM), and sleep apnea), and
to metabolic disturbances [4–7]. The TE type has a
higher level of body mass index (BMI), triglycerides
(TG), and blood pressure (BP) compared with the SY
and SE types [5–7]. Moreover, the TE type is regarded
as an independent risk factor for HTN [5], DM [7], and
sleep apnea [6]. The TE and SY types have a higher risk
for metabolic syndrome (MS) [8], a cluster of metabolic
risk factors characterized by high BP, high blood glu-
cose, low high-density lipoprotein (HDL) cholesterol,
and abdominal obesity, compared with the SE type.
Non-alcoholic fatty liver disease (NAFLD) is the most
common cause of chronic liver disease. It includes a
wide spectrum of conditions, such as non-alcoholic
steatohepatitis (NASH) with or without fibrosis, cirrho-
sis, and associated complications [9, 10]. Patients have
no or a low daily alcohol consumption (≤ 30 g/day for
men, ≤ 20 g/day for women) [11]. The prevalence of
NAFLD in the general population varies in different
epidemiologic studies. In the US [12] and Europe [11, 13],
researchers report a 10-35 % and 20-30 % prevalence of
NAFLD, respectively. Similar to the US, the estimated
prevalence of NAFLD in the Asia-Pacific region ranges
from 5 % to 30 % [14]. In Korea, NAFLD prevalence
ranges from 18 % to 22 % [15, 16].
NAFLD has a close relationship with type II DM and
features of MS. It was reported that the prevalence of
NAFLD in patients with type II DM was 69 % [17]. The
prevalence of simple steatosis in the obese ranges from
30 % to 37 % [18, 19]. Moreover, insulin resistance has
been shown to be positively correlated with the degree
of steatosis [20]. Conversely, patients with steatosis had
higher BMIs, insulin resistance scores, waist/hip ratios,
and TG [21].
Although specific SCTs are independent risk factors
for pathologic conditions such as DM and MS, which
are highly associated with NAFLD and account for
metabolic disturbances, there is a lack of research about
the relationship between the SCTs and NAFLD. The
identification of the specific SCTs who are vulnerable to
NAFLD may be helpful in predicting susceptibility to
the disease, early intervention, and management of high-
risk individuals. With this in mind, we investigated the




The subjects were selected from cohort members who
enrolled in the Korean Genome and Epidemiology Study
(KoGES). Among 1824 participants who were both
followed-up and grouped as an SCT from 2009 to 2011,
1479 individuals who completed computed tomography
(CT) scanning were selected for the analysis. There were
no significant differences in aspartate aminotransferase
(AST) and alanine aminotransferase (ALT) levels in
1824 participants followed-up and in the remaining
cohort members who were lost during the period
between 2009 and 2011. Then, 295 subjects who had
heavy alcohol intake (more than 140 g/week for men,
70 g/week for women), 69 subjects who had a history of
viral infection (hepatitis B antigen or hepatitis C antigen
positive), and five subjects who suffered a chronic liver
disease including hepatocellular carcinoma and cirrhosis,
were excluded from the analysis [22]. The remaining
1184 subjects (508 males, 676 females) were ultimately
analyzed in the study. Each participant signed written
informed consent form before the examination. Subjects
underwent physical examinations, laboratory and ques-
tionnaire evaluations, and a review of their medical
histories. The study protocol was approved by the
Institutional Review Board of Korea University Ansan
Hospital. Consistent with the previous finding that the
TY type is extremely low in the population [7], there
were no subjects classified as the TY type in our study.
Therefore, only the data from the TE, SE, and SY types
was evaluated in the present study.
Classification of the SCTs
Each constitutional type was classified by an integrated
Sasang constitutional diagnostic model developed by
Do et al. [23]. Unlike the Questionnaire for Sasang
Constitutional Classification II (QSCC II), a commonly
used questionnaire focusing on individual qualitative
components to determine the SCT [24], this newly
developed diagnostic model integrates four individual
quantitative components, including facial image, body
shape, voice analysis, and questionnaire responses into
a single model, increasing the validity of the diagnostic
model. The accuracy of the current diagnostic method
is higher than that of QSCC II (64 % in males and
55.2 % in females in an integrated diagnostic model vs.
51 % in total with the QSCC II).
Feature variables were acquired from facial images taken
with a digital camera and automatically extracted via
image processing techniques. As candidate variables to
express body shape characteristics, the following parame-
ters were measured or calculated: forehead circumference,
neck circumference, axillary circumference, chest circum-
ference, rib circumference, waist circumference, pelvic
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circumference, hip circumference, height, weight, and
body mass index. For voice analysis in the diagnostic
model, more than eighty features were extracted by two
voice analysis programs, Hidden Markov Model Toolkit
and Praat, and processed with a genetic algorithm-based
feature selection technique. Each subject also completed a
questionnaire composed of 67 multiple-choice questions
with binary variables representing personality characteris-
tics and physiologic symptoms.
Diagnosis of NAFLD
NAFLD was diagnosed using non-invasive computed
tomography (CT) scanning. Study procedures for CT are
available in a previous report [25]. Briefly, the abdominal
adipose tissue area was quantified by a single slice CT
scan (Brilliance 64; Philips, Cleveland, OH, USA) and
the images were converted into files compatible with a
commercial software program (EBW; Philips, Cleveland,
OH, USA). The liver attenuation index (LAI), derived
from the difference between the mean hepatic and
splenic attenuation, was used as a parameter for the
diagnosis of NAFLD. A LAI of <5 Hounsfield Units
(HU) is a known predictor of >5 % steatosis [26], and
histological confirmation of NAFLD requires a mini-
mum of 5 % steatosis [27]. Therefore, NAFLD was
defined when the LAI value was <5 HU in this study.
Anthropometric measurements and definition of variables
and disease
BMI was calculated as weight in kilograms divided by
the square of the height in meters (kg/m2) measured to
the nearest 0.1 cm or 0.1 kg. Waist circumference (cm)
was measured at the narrowest point between the lower
rib and the iliac crest. BP was measured in a sitting pos-
ition with a mercury sphygmomanometer on the non-
dominant arm. We calculated beverage-specific alcohol
consumption in g/day on the basis of the alcohol con-
tent (4.5 % for beer, 13 % for wine, 40 % for hard liquor,
22 % for soju, 15 % for chungju, and 6 % for makgeolli),
the frequency of drinking, and the amount consumed as
previously reported [28]. Leisure-time physical activity
was evaluated using questionnaires covering the type of
activity, frequency, and duration. A metabolic equivalent
(MET) score was assigned to each sports activity based
on the compendium of physical activities. Time spent
per week performing each activity was multiplied by the
MET value of the activity to obtain the total MET-
minutes per week. MS was defined according to the
modified version of a diagnostic criteria proposed by the
National Cholesterol Education Program Adult Treat-
ment Panel III [29], as the presence of three or more of
the following clinical criteria: central obesity based on
Asia–Pacific criteria (waist circumference ≥90 cm for
men and ≥80 cm for women), hypertriglyceridemia
(TG ≥150 mg/dl), low HDL cholesterol (HDL choles-
terol <40 mg/dl for men and <50 mg/dl for women), high
BP (systolic/ diastolic pressure ≥130/80 mmHg or use of
antihypertensive medication), and high fasting glucose
(fasting glucose ≥110 mg/dl or use of antihyperglycemic
agents). The homeostasis model of assessment for insulin
resistance (HOMA-IR) was calculated as fasting glucose
(mmol/L) x fasting insulin (μU/mL)/22.5. All biochemical
analyses for TG, fasting plasma glucose, and HDL choles-
terol were conducted in the Seoul Clinical Laboratories
(Seoul, South Korea). HTN was defined as systolic
BP ≥ 140 mmHg, diastolic BP ≥ 90 mmHg, or the use
of antihypertensive medication [30]. DM was defined
when fasting glucose exceeded 126 mg/dl or antihy-
perglycemic agents or insulin were used. Obesity was
defined as BMI ≥ 27.5 based on the guideline for
Asian populations [31].
Statistical analysis
Data are expressed as a mean ± standard deviation (SD).
The significant differences of the means were evaluated
using one-way analysis of variance (ANOVA) for
continuous variables and chi-square test for categorical
variables. Bonferroni’s post hoc test was performed for
multiple comparisons. In addition, we conducted a mul-
tiple logistic regression analysis to estimate an odds ratio
(OR) of the presence of NAFLD in relation to different
SCTs with a 95 % confidence interval (CI) and P value.
The potential confounding variables adjusted in the
multivariate Model 1 were age, sex, BMI, alcohol con-
sumption, alanine aminotransferase (ALT), and physical
activity. Model 2 added the presence of each metabolic
component (abdominal obesity, hypertriglyceridemia,
low HDL cholesterol, high BP, and high fasting plasma
glucose) to Model 1. We also conducted an additional
multiple logistic regression to identify an independent
association only in the non-obese group. Statistical ana-
lysis was performed with SAS version 9.3 (SAS Institute,
Cary, North Carolina, USA). All P values <0.05 were
considered as statistically significant.
Results
General characteristics of participants
A total 1184 subjects (508 males and 676 females) who
completed CT scanning were included in the analysis.
The general characteristics of the participants according
to their SCTs are shown in Table 1. The mean age of
total subjects was 57.3 ± 7.4 years. The TE type was
older, obese, and has a lower proportion of females than
the other types. The TE type consumed more alcohol
and had higher levels of ALT and HOMA-IR than the
other two types. The prevalence of HTN, DM, and
NAFLD was the highest in the TE type compared with
the SE and SY types. Compared with the SE type, the SY
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had a significantly higher prevalence of NAFLD. LAI in
the TE type was lower than those of the SE and SY types.
Values of all metabolic components were significantly
higher in the TE type compared with the other types.
The TE type had the highest prevalence of MS among
the SCTs. Physical activity was not statistically different
among the SCTs.
Odds ratios (ORs) for NAFLD according to the SCTs
In order to estimate ORs for NAFLD in relation to
constitutional types, a logistic regression analysis was
conducted (Table 2). Under crude analysis, the SY and
TE types were more likely to have NAFLD compared
with the SE type. In the analysis adjusted for age, sex,
BMI, alcohol consumption, ALT, and physical activity
(Model 1), the SY and TE types had 4.21 times (95 % CI,
1.75-10.13; P = 0.0028) and 3.31 times (95 % CI: 1.43-7.67,
P = 0.0051) higher odds of having NAFLD than that of the
SE type, respectively. In the analysis additionally adjusted
for all metabolic components (Model 2), the SY and TE
types continued to show a 3.90-fold (95 % CI, 1.60-9.51;
P = 0.0028) and a 3.36-fold (95 % CI, 1.42-7.92, P = 0.0057)
greater chance of having NAFLD than the SE type,
respectively.
Odds ratios (ORs) for NAFLD in the non-obese subjects
according to the SCTs
To evaluate the association between NAFLD and the
SCTs in non-obese subjects, we excluded subjects having
BMIs ≥ 27.5 (n = 190), and the remaining 994 par-
ticipants were used in the analysis (Table 3). In the
multivariate analysis (Model 2) for the association
Table 1 General characteristics according to Sasang constitution type
Variable SE SY TE P value
No. of cases 172 407 605
Age (yr) 55.3 ± 6.0a** 56.0 ± 6.4** 58.8 ± 7.9 <.0001
Female, n (%) 94 (54.7)***** 285 (70.0)** 297 (49.1) <.0001
BMI (kg/m2) 21.3 ± 1.6**,****** 22.9 ± 2.0** 26.6 ± 2.4 <.0001
Alcohol consumption (g/day) 1.8 ± 4.0* 1.8 ± 3.9** 3.1 ± 5.3 <.0001
ALT (IU/L) 23.1 ± 24.1* 21.8 ± 10.0** 27.3 ± 16.2 <.0001
HOMA-IRb 1.5 ± 0.6** 1.7 ± 0.8** 2.6 ± 3.5 <.0001
Physical activityc 159.5 ± 195.5 189.7 ± 276.4 189.0 ± 258.2 0.37
LAI (HU) 13.3 ± 6.0** 12.3 ± 7.0** 6.5 ± 9.9 <.0001
NAFLD [LAI < 5, n (%)] 8 (4.7)**,**** 57 (14.0)** 206 (34.0) <.0001
HTN, n (%) 35 (20.3)** 99 (24.3)** 266 (44.0) <.0001
DM, n (%) 13 (7.6)** 50 (12.3)** 164 (27.1) <.0001
Metabolic componentsd
Abdominal obesity, n (%) 5 (2.9)**,*** 35 (8.6)** 293 (48.5) <.0001
Hypertriglyceridemia, n (%) 28 (16.3)**,*** 100 (24.6)** 248 (41.0) <.0001
Low HDL cholesterol, n (%) 122 (70.9)**,**** 232 (57.0)** 293 (48.4) <.0001
High BP, n (%) 45 (26.2)** 124 (30.6)** 317 (52.7) <.0001
High FPG, n (%) 8 (4.7)**,*** 40 (9.8)** 140 (23.1) <.0001
MS, n (%)e 6 (3.5)**,**** 41 (10.1)** 233 (38.5) <.0001
Abbreviations: TE Tae-eum type, SE So-eum type, SY So-yang type, BMI body mass index, ALT alanine aminotransferase, HOMA-IR homeostasis model of assessment
for insulin resistance, MET metabolic equivalents, LAI liver attenuation index, HU Hounsfield units, NAFLD non-alcoholic fatty liver disease, HTN hypertension,
DM diabetes mellitus, HDL high density lipoprotein, BP blood pressure, FPG fasting plasma glucose, MS metabolic syndrome
aValues are mean ± SD
bCalculated as fasting glucose (mmol/L) x fasting insulin (μU/mL)/22.5
cTotal metabolic equivalents per week (minutes)
dDefined as waist circumference ≥90 cm for men and ≥80 cm for women for abdominal obesity; TG ≥150 mg/dl for hypertriglyceridemia; HDL cholesterol <40 mg/dl for
men and <50 mg/dl for women for low HDL cholesterol; systolic/ diastolic pressure ≥130/85 mmHg for high BP; fasting plasma glucose ≥110 mg/dl for high FPG
ePresence of 3 or more of metabolic components
*P <0.01 vs. TE type
**P <0.0001 vs. TE type
***P <0.05 vs. SY type
****P <0.01 vs. SY type
*****P <0.001 vs. SY type
******P <0.0001 vs. SY type
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between NAFLD and the SCTs, the ORs of NAFLD were
3.27-fold (95 % CI, 1.29-8.29, P = 0.0126) for the SY type,
and 3.53-fold (95 % CI, 1.30-9.58; P = 0.0134) for the TE
type, greater than the SE type.
Logistic regression analysis of possible risk factors for
NAFLD in the SY and TE types
We conducted an additional multivariate logistic re-
gression analysis with possible risk factors for NAFLD to
determine which parameters had an independent associ-
ation with NAFLD in the SY and TE types. In the SY
type, higher BMI, ALT, TG, and low HDL cholesterol
were independently associated with developing NAFLD.
In contrast, male sex, alcohol consumption, higher ALT,
TG, and fasting glucose were the risk factors for NAFLD
in the TE type. Only two common factors, higher ALT
and TG, were seen in both the SY and the TE types.
Discussion
The present cohort study found that the SY and TE
types are associated with an increased risk of NAFLD,
even after taking into account possible confounders, in-
dependent of obesity. We also found that the risk factors
for NAFLD are different in the SY and TE types.
The interesting finding was that, although the SY type
had a lower value or prevalence of risk factors for
NAFLD than the TE type, the risk of having NAFLD was
higher in the SY type than the TE type. The reason why
the ORs for NAFLD is different is unknown, but, as
revealed by logistic regression analysis of possible risk
factors for NAFLD in Table 4, it may be due to the
difference in the sensitivity to each risk factor between
the SY and TE types. For example, high BMI, TG, and
low HDL cholesterol were significant risk factors for
NAFLD in the SY type, but they were not in the TE type.
On the other hand, male sex, alcohol consumption, and
high fasting glucose were the risk factors only in the TE
type. Further studies are required to clarify what causes
this difference among the SCTs.
Because NAFLD is strongly associated with obesity
[12, 32] and our SCTs had a significantly different degree
of obesity, we repeated the analysis to examine the
association between NAFLD and the SCTs in non-obese
subjects having BMI <27.5 (Table 3). Similar to the
results of the multivariate analysis including all subjects
(Table 2), the SY and TE types continued to show a
significantly higher risk of having NAFLD compared
with the SE type, implying that obesity is not a major
risk factor for NAFLD in the SY and TE types. The ORs,
however, was higher in the TE type than in the SY type,
inconsistent with the results of Table 2. Obesity is a
cause of NAFLD’s increasing prevalence in western
countries [33, 34], but obesity as a risk factor for NAFLD
may not be generalizable to Asian populations. In cohort
studies, a high prevalence of NAFLD was reported in the
Asians who had significantly lower BMI [35, 36].
Although not entirely elucidated, one possible explanation
for the discrepancy between obesity and NAFLD is the
ethnic differences in the distribution of body fat, given
that Asians have a more central adiposity and visceral fat
deposition [37–40].
The reason why the SY and TE type have higher risk
of having NAFLD than the SE type is unknown, but
several speculations could be made. First, dysfunctions
of lipid metabolism pathway caused by genetic variations
can exist in those types. It has been previously reported
that the TE type is associated with genetic variants of
pathways which have previously been reported to cause
HTN [41, 42]. However, there have been no studies that
Table 3 Odds ratio of NAFLD in relation to Sasang constitution
type in non-obese subjects
Estimated odds ratios of NAFLD (95 % CI)
SE SY TE
No. of normal cases (%) 164 (95.9) 345 (86.3) 297 (70.2)
No. of NAFLD cases (%) 7 (4.1) 55 (13.8) 126 (29.8)












Abbreviations: TE Tae-eum type, SE So-eum type, SY So-yang type, NAFLD non-
alcoholic fatty liver disease
aModel 1: adjusted for age, sex, BMI, alcohol consumption, ALT, and
physical activity
bModel 2: adjusted for Model 1 +metabolic components
Non-obese was defined as BMI <27.5
Table 2 Odds ratio of NAFLD in relation to Sasang
constitution type




164 (95.4 %) 349 (86.0 %) 399 (66)
No. of NAFLD
cases (%)
8 (4.6) 58 (14.0) 206 (34)












Abbreviations: TE Tae-eum type, SE So-eum type, SY So-yang type, NAFLD non-
alcoholic fatty liver disease
aModel 1: adjusted for age, sex, BMI, alcohol consumption, ALT, and
physical activity
bModel 2: adjusted for Model 1 +metabolic components
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investigated the association between specific genetic
polymorphisms related with dysfunctions of lipid metab-
olism and SCTs, thus further studies are required.
Second, sleep apnea also may contribute to the NAFLD
in TE and SY types. We previously reported that TE and
SE type had a 2.3 and 1.9 greater risk of having ob-
structive sleep apnea (OSA), respectively, compared to
the SE type [6]. Given that OSA is associated with
NAFLD [43, 44], the presence of OSA in these types
could partially explain why the types had greater risk for
NAFLD compared to the SE type.
The main strength of our study includes its
randomly-sampled population-based study design and
the large sample size. There are some limitations worth
noting in this study. First, we identified NAFLD by CT
scanning, not by liver biopsy, which is the diagnostic
gold standard for NAFLD [45]. Additionally, the identi-
fication of chronic liver disease, to exclude it from the
analysis, was done based on a questionnaire, increasing
the chance of underestimated NAFLD prevalence. But
it is not possible to perform liver biopsies in an epi-
demiological study because it is an invasive, dangerous,
and time-consuming procedure. CT is a good alterna-
tive method because it is non-invasive and performs
well in the diagnosis of greater degrees of steatosis
(>30 %) with a sensitivity of 82 % and a specificity of
100 % [25]. Thus, it is more suitable for diagnosis of
NAFLD than liver biopsy in the cohort study. Second,
the age distribution of the study participants was not
even, but biased toward middle age. The prevalence of
NAFLD increases with age, and therefore, the present
findings cannot be generalized to young age groups.
Third, accuracy of classification method used in this
study is low (64 % in males and 55.2 % in females).
Fourth, dietary information, including amount of fat
intake, was not examined in the present study.
Conclusions
The SY and TE types are independent risk factors for
NAFLD. These findings may contribute to the early
prevention and management of high-risk individuals of
NAFLD according to the SCTs, and ultimately, to
personalized medicine. Further investigation is needed
to confirm the risk factors for NAFLD according to the
SCTs and to explore the physiological mechanisms
underlying the association.
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